Navigation Links
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Date:2/11/2008

r survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release anticipating future clinical and business prospects for our lead drug candidate Sulonex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: the results of the Phase 3 study for Sulonex could be inconclusive or negative; even if we receive positive results from the Phase 3 study for Sulonex, we may not be able to finalize the NDA before year end for various reasons including the completion of necessary non- clinical studies; the completion of manufacturing preparations; or other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

Keryx Contact:

Lauren Fischer

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015   Gulf Coast Tattoo Removal is ... the cutting-edge Astanza Duality laser in Southern Mississippi ... their tattoo regret and take back control of their skin. The ... extends its services to Biloxi , ... "With tattoo regret being as prevalent as it is, I was ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ) ... Introduction to Medical Device Software: Regulations and Requirements ... to their offering. This course ... and requirements that apply to Medical Device Software. ... life examples and state-of- the-art practices identified from ...
(Date:9/2/2015)... , Sept. 2, 2015  Research and ... of the "An Introduction to the Medical ... conference to their offering. ... European medical device legislation. It will explain the ... of Notified Bodies, how to choose one and ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... TRIANGLE PARK, N.C., Oct. 17 CeNeRx BioPharma,Inc., ... for diseases of the central nervous system, today ... trial for its lead product candidate,Tyrima(TM) for the ... selective and reversible member of a novel class ...
... Berlin Heart Inc. today announced,its EXCOR(R) Pediatric ventricular assist ... clinical trial in the United,States of America. The U.S ... Plan for the IDE study of the device., ... the prospective,IDE study to begin initially at 10 centres ...
Cached Medicine Technology:CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 3Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 2Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 3
(Date:9/2/2015)... ... September 02, 2015 , ... ... large stream of mixed documents that include EOBs, payments, and payment related documents. ... the data needed to reconcile their billing, with one efficient process and interface,“ ...
(Date:9/2/2015)... Pittsburgh, PA (PRWEB) , ... September 02, 2015 ... ... the Health Sciences clinical and academic partnership has earned international recognition as a ... rare genetic disorder that can cause sudden, catastrophic internal bleeding and stroke. ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... largest and fastest-growing interim clinical staffing companies, has completed a recapitalization with ... , BPOC and Heritage Group each offer extensive expertise and ...
(Date:9/2/2015)... Kansas City, KS (PRWEB) , ... September 02, 2015 , ... ... recently opened its newest office in Kansas – its Johnson County location. ... backgrounds in healthcare. Mike has a registered nurse background and spent over 20 years ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be ... risk of getting ovarian cancer in her lifetime is approximately 1 in 75. This ... ovarian cancer, and 14,000 will die. , There is no test to detect ...
Breaking Medicine News(10 mins):Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3
... , , WASHINGTON, July 24 ... today in support of the minimum wage increase from $6.55 an hour ... minimum wage increase is an important step in recovering our economy, rebuilding ... it is only one of three prongs necessary to create a real ...
... common, but labeling is not required, report states , ... "enhance" uncooked meat and poultry can pose serious health ... Many fresh meat and poultry products are injected with ... not required to be listed on food labels, according ...
... , , CLEVELAND, July 24 /PRNewswire/ ... access for the uninsured and underinsured to a wide range of health ... 25 and 26, at the W.O. Walker Center, 10524 Euclid Ave. The ... provide 1100 medical, 300 vision and 200 dental patient visits. Appointments ...
... , CHICAGO, July 24 ... in designing and manufacturing portable rechargeable systems, today ... single-output power supplies. The new 350-watt series, designed ... delivers an industry-leading converter efficiency of up to ...
... WESTBROOK, Maine, July 24 IDEXX Laboratories, Inc. (Nasdaq: ... second quarter of 2009 were $265.7 million compared to $280.6 ... as defined below, was 5%. Earnings per diluted share ("EPS") ... to $0.63 for the same period in the prior year. ...
... ... Texans find affordable, direct access to medical lab testing through Any Lab Test Now®. , ... Plano, TX (PRWEB) July 24, 2009 -- This ... company has found its niche. Opened December 2008, Any Lab Test Now® in ...
Cached Medicine News:Health News:Fresh-Meat Additives May Be Dangerous for Kidney Patients 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:Convection Cooled 350-Watt Open Frame Power Supply Meets Medical and Industrial Safety Standards 2Health News:IDEXX Laboratories Announces Second Quarter Results 2Health News:IDEXX Laboratories Announces Second Quarter Results 3Health News:IDEXX Laboratories Announces Second Quarter Results 4Health News:IDEXX Laboratories Announces Second Quarter Results 5Health News:IDEXX Laboratories Announces Second Quarter Results 6Health News:IDEXX Laboratories Announces Second Quarter Results 7Health News:IDEXX Laboratories Announces Second Quarter Results 8Health News:IDEXX Laboratories Announces Second Quarter Results 9Health News:IDEXX Laboratories Announces Second Quarter Results 10Health News:IDEXX Laboratories Announces Second Quarter Results 11Health News:IDEXX Laboratories Announces Second Quarter Results 12Health News:IDEXX Laboratories Announces Second Quarter Results 13Health News:IDEXX Laboratories Announces Second Quarter Results 14Health News:IDEXX Laboratories Announces Second Quarter Results 15Health News:IDEXX Laboratories Announces Second Quarter Results 16Health News:IDEXX Laboratories Announces Second Quarter Results 17Health News:IDEXX Laboratories Announces Second Quarter Results 18Health News:IDEXX Laboratories Announces Second Quarter Results 19Health News:IDEXX Laboratories Announces Second Quarter Results 20Health News:IDEXX Laboratories Announces Second Quarter Results 21Health News:IDEXX Laboratories Announces Second Quarter Results 22Health News:Cost-Conscious Texans Find Relief with Direct Access Lab Testing 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: